Cyclacel Surges 2793.82% in Trading Volume, Ranks 344th in Market

On July 18, 2025, Cyclacel's trading volume reached 3.29 billion, marking a significant increase of 2793.82% compared to the previous day. This surge placed Cyclacel at the 344th position in the day's stock market rankings. Cyclacel (CYCC) has been on a bullish streak, rising by 58.81% and experiencing a 6.00% increase over the past five days.

Cyclacel Pharmaceuticals, Inc. has announced that it has entered into a collaboration agreement with a leading biotechnology company to develop novel cancer therapies. This strategic partnership aims to leverage the strengths of both companies to accelerate the development of innovative treatments for patients with unmet medical needs.

Cyclacel Pharmaceuticals, Inc. has reported positive interim results from its ongoing Phase 2 clinical trial of CYC140, an oral CDK inhibitor, in patients with advanced solid tumors. The trial has shown promising anti-tumor activity and a favorable safety profile, supporting further development of the drug.

Cyclacel Pharmaceuticals, Inc. has announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a patent covering its proprietary CDK inhibitor technology. This patent, once issued, will provide Cyclacel with exclusive rights to develop and commercialize CDK inhibitors for the treatment of various cancers.